{"filing":{"accession_number":"0001193125-26-323940","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"dyn-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-20260729.htm"},"events":[{"id":21727,"run_id":19600,"accession_number":"0001193125-26-323940","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Dyne Therapeutics issued a press release on July 29, 2026 announcing financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $152.2 million, G\u0026A expenses of $29.5 million, and a net loss of $178.6 million ($1.08 per share). The press release is furnished as Exhibit 99.1 and discloses quarterly operating results, cash position, and financial metrics typical of an earnings release under Item 2.02.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21432,"accession_number":"0001193125-26-323940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Dyne Therapeutics issued a press release on July 29, 2026 announcing financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $152.2 million, G\u0026A expenses of $29.5 million, and a net loss of $178.6 million ($1.08 per share). The press release is furnished as Exhibit 99.1 and discloses quarterly operating results, cash position, and financial metrics typical of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:08:58.213918+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21432,"accession_number":"0001193125-26-323940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Dyne Therapeutics issued a press release on July 29, 2026 announcing financial results for the quarter ended June 30, 2026, including R\u0026D expenses of $152.2 million, G\u0026A expenses of $29.5 million, and a net loss of $178.6 million ($1.08 per share). The press release is furnished as Exhibit 99.1 and discloses quarterly operating results, cash position, and financial metrics typical of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:08:58.213918+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-07-29"}]}